How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Congenital Heart Defect Repair Market
- By Defect Type: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Patent Ductus Arteriosus (PDA), Tetralogy of Fallot (TOF), Coarctation of the Aorta, Transposition of the Great Arteries (TGA)
- By Treatment Modality: Surgical Repair, Catheter-Based Interventions, Hybrid Procedures, Medical Management
- By Device Type: Occluder Devices, Patch Materials, Valves and Valve Replacements, Stents, Sutures and Surgical Instruments
- By Patient Age Group: Neonates, Infants, Pediatrics, Adolescents, Adults with Congenital Heart Defects
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Atrial Septal Defect (ASD) leads By Defect Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.169 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.177 →
Full report · locked preview
Everything inside the Congenital Heart Defect Repair Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Defect Type 6
Treatment Modality 4
Device Type 5
Patient Age Group 5
Companies profiled
Medtronic plc
Abbott Laboratories
Edwards Lifesciences Corporation
Boston Scientific Corporation
Terumo Corporation
LivaNova PLC
Stryker Corporation
Johnson & Johnson (Ethicon)
Becton
Dickinson and Company (BD)
W.L. Gore & Associates
Cook Medical
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Edwards Lifesciences Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →LivaNova PLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Stryker Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Johnson & Johnson (Ethicon)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →W.L. Gore & Associates
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cook Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Penumbra Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →MicroPort Scientific Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Cardinal Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Philips Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,744M by 2033 · 8.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Atrial Septal Defect (ASD)30.4
- Ventricular Septal Defect (VSD)11.7
- Patent Ductus Arteriosus (PDA)11.0
- Tetralogy of Fallot (TOF)18.3
- Coarctation of the Aorta16.7
- Transposition of the Great Arteries (TGA)11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,476M → $3,030M · 9.4%
Europe$1,029M → $2,036M · 8.9%
Asia Pacific$939.4M → $2,014M · 10.0%
Latin America$581.5M → $1,267M · 10.2%
Middle East and Africa$447.3M → $847.4M · 8.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.702026
8.712027
8.722028
8.732029
8.742030
8.742031
8.762032
8.772033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic plc19.6
- Abbott Laboratories14.4
- Edwards Lifesciences Corporation13.0
- Boston Scientific Corporation13.3
- Terumo Corporation5.2
- LivaNova PLC6.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Defect Type35.8%
Treatment Modality22.7%
Device Type18.5%
Patient Age Group23.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe22.1
- Asia Pacific21.9
- Latin America13.8
- Middle East and Africa9.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 99 | 82 | 89 | 82 | 80 | 87 | 87 |
| Abbott Laboratories | 90 | 75 | 87 | 74 | 81 | 77 | 81 |
| Edwards Lifesciences Corporation | 65 | 63 | 73 | 82 | 73 | 77 | 72 |
| Boston Scientific Corporation | 60 | 80 | 61 | 71 | 57 | 61 | 65 |
| Terumo Corporation | 66 | 57 | 65 | 63 | 68 | 62 | 64 |
| LivaNova PLC | 54 | 64 | 47 | 68 | 61 | 71 | 61 |
| Stryker Corporation | 46 | 56 | 49 | 48 | 52 | 60 | 52 |
| Johnson & Johnson (Ethicon) | 48 | 43 | 58 | 38 | 57 | 48 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic plc
- Abbott Laboratories
- Edwards Lifesciences Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic plc | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Abbott Laboratories | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Edwards Lifesciences Corporation | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Boston Scientific Corporation | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Terumo Corporation | − | ◐ | ◐ | ✓ | − | − |
| LivaNova PLC | − | ◐ | ◐ | ✓ | ◐ | ◐ |
| Stryker Corporation | ◐ | ◐ | ◐ | − | − | ◐ |
| Johnson & Johnson (Ethicon) | − | − | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic plc87
2Abbott Laboratories81
3Edwards Lifesciences Corporation72
4Boston Scientific Corporation65
5Terumo Corporation64
6LivaNova PLC61
7Stryker Corporation52
8Johnson & Johnson (Ethicon)49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Medtronic plcAbbott Laboratories
Challenger1
Strong scale, closing on the leaders.
Edwards Lifesciences Corporation
Contender3
Focused players with pockets of strength.
Boston Scientific CorporationTerumo CorporationLivaNova PLC
Niche2
Specialists in a single segment or region.
Stryker CorporationJohnson & Johnson (Ethicon)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Defect Type in North America, then scale across Congenital Heart Defect Repair Market — a $535M beachhead inside a $8.07B market.
Beachhead (SOM)$535Mobtainable near-term
Serviceable (SAM)$3.06Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Atrial Septal Defect (ASD)
Best fit — highest urgency & budget in Defect Type.
Economic buyer75 fit
Ventricular Septal Defect (VSD)
Strong fit — clear ROI and a fast path to value.
End user66 fit
Patent Ductus Arteriosus (PDA)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Defect Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Device Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel31%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Defect Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Congenital Heart Defect Repair Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified24%
Evaluation13%
Closed-won5%
$12.7KCAC
$71KLTV
5.6:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Congenital Heart Defect Repair Market is a durable-growth opportunity — $7.39B by 2033, compounding at 6.4%.
TAM · 2025$4.51Btoday
TAM · 2033$7.39Bforecast
CAGR6.4%2027–2033
Cumulative$52.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.39BTotal addressable market
SAM$2.62BServiceable available market
SOM$487MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.4% CAGR
Demand compounds through 2033, outpacing GDP across Defect Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Defect Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.39BLarge & growingTAM by 2033 at 6.4% CAGR
$2.62BServiceable nowreachable with today’s model
$487MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.77BBear4.1% CAGR
$7.39BBase6.4% CAGR
$9.46BBull8.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Congenital Heart Defect Repair Market — a $6.18B market by 2033. Plan: grow share from 10.2% to 16.1%.
Market size · 2033$6.18Btotal addressable
Market CAGR3.8%2027–2033
Target share16.1%from 10.2% today
Revenue ambition$996Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.2% | 16.1% | At risk |
| Revenue | $571M | $996M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 35.3% | 38.1% | On track |
| Customer retention | 89.9% | 95.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Defect Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Defect Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $111M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Defect Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Congenital Heart Defect Repair Market conversation — a $6.94B market you can size, segment and defend in minutes.
Market size · 2033$6.94Btotal opportunity
Growth5.0%CAGR to 2033
Addressable buyers1,325+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Defect Type
Goal Grow share in Defect Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 4 mopayback period
$75K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Medtronic plcAbbott LaboratoriesEdwards Lifesciences CorporationBoston Scientific CorporationTerumo CorporationLivaNova PLCStryker CorporationJohnson & Johnson (Ethicon)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Congenital Heart Defect Repair Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Congenital Heart Defect Repair Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Congenital Products Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCongestive Heart Failure (Heart Failure) Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportCongestive Heart Failure Drug Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCongestive Heart Failure Treatment Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportConical Anti-Vibration Isolation Mounts Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportConical Double-Worm Mixer Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportConical Horn Antenna Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportConical Spring Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportConical Spring Mechanical Seals Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportConical Twin Screw Barrel Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportConjugated Drug Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportConjugated Estrogens Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.